Stockscreener 앱 받기
5.09
4.52%
0.22
시간 외 거래:
5.19
0.10
+1.96%
전일 마감가:
$4.87
열려 있는:
$4.86
하루 거래량:
95,230
Relative Volume:
2.00
시가총액:
$22.76M
수익:
$86.55M
순이익/손실:
$-56.70M
주가수익비율:
-1.9795
EPS:
-2.5713
순현금흐름:
$4.87M
1주 성능:
-0.78%
1개월 성능:
-17.06%
6개월 성능:
+13.67%
1년 성능:
-13.73%
1일 변동 폭
$4.86
$5.30
1주일 범위
$4.56
$5.30
52주 변동 폭
$2.813
$9.458
Harvard Bioscience Inc Stock (HBIO) Company Profile
명칭
Harvard Bioscience Inc
전화
(508) 893-8999
주소
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
5.09 | 21.78M | 86.55M | -56.70M | 4.87M | -2.5713 |
ISRG
Intuitive Surgical Inc
|
464.45 | 163.73B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.34 | 44.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.51 | 36.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.00 | 36.12B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
222.85 | 32.70B | 5.40B | 1.49B | 1.78B | 10.12 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 개시 | Northland Capital | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-01-24 | 재확인 | Janney | Buy |
| 2018-01-23 | 재확인 | The Benchmark Company | Buy |
| 2016-11-17 | 개시 | Singular Research | Buy |
| 2015-07-28 | 개시 | The Benchmark Company | Buy |
모두보기
Harvard Bioscience Inc 주식(HBIO)의 최신 뉴스
Harvard Bioscience CFO Frost buys $25,000 in HBIO stock - investing.com
Harvard Bioscience (NASDAQ: HBIO) CFO awarded 30,000 RSUs in equity grant - Stock Titan
Harvard Bioscience (HBIO) CFO adds 5,000 shares at $5.00 - Stock Titan
Harvard Bioscience outlines 2026 guidance with 2%–4% revenue growth and high-margin focus following structural improvements - MSN
Is Harvard Bioscience Inc stock a top performer YTD2026 Growth vs Value & Reliable Entry Point Alerts - baoquankhu1.vn
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Debt to assets ratio of Harvard Bioscience, Inc. – MUN:HBI0 - tradingview.com
Trading Recap: Is Harvard Bioscience Inc forming a bullish divergenceWeekly Investment Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
EBIT of Harvard Bioscience, Inc. – MUN:HBI0 - TradingView
HARVARD BIOSCIENCE (NASDAQ: HBIO) CEO receives 75,000-share stock grant - Stock Titan
William Snider Secures Board Seat at Harvard Bioscience with 15.97% Stake - TradingView
BroadOak reports 16% Harvard Bioscience (HBIO) stake tied to loans and warrants - Stock Titan
Harvard Bioscience stock faces scrutiny amid Q4 earnings anticipation and life sciences sector volat - ad-hoc-news.de
Taxes of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Harvard Bioscience Outlines Post-Refi Strategy, Organoid Growth Focus - National Today
Total equity of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Free cash flow per share of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Equity in earnings of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Equity in earnings of Harvard Bioscience, Inc. – GETTEX:HBI0 - TradingView
Cash per share of Harvard Bioscience, Inc. – GETTEX:HBI0 - TradingView
Harvard Bioscience, Inc. Cash Flow – GETTEX:HBI0 - TradingView
Net income of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Price to earnings ratio of Harvard Bioscience, Inc. – GETTEX:HBI0 - TradingView
Net debt of Harvard Bioscience, Inc. – LSX:A423J5 - TradingView
Return on assets % of Harvard Bioscience, Inc. – LSX:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
Insider Buying: Stephen Denelsky Acquires 10,000 Shares of Harva - gurufocus.com
Harvard Bioscience (HBIO) director Denelsky buys $48,700 in shares By Investing.com - Investing.com India
Harvard Bioscience (HBIO) director Denelsky buys $48,700 in shares - Investing.com
Harvard Bioscience (NASDAQ:HBIO) Director Stephen Denelsky Purchases 10,000 Shares - MarketBeat
Harvard Bioscience (HBIO) director buys 10,000 shares in open market - Stock Titan
Harvard Bioscience director Snider buys $103,603 in HBIO stock By Investing.com - Investing.com Australia
Harvard Bioscience (NASDAQ:HBIO) Director William Snider Acquires 12,525 Shares - MarketBeat
Harvard Bioscience director Snider buys $103,603 in HBIO stock - Investing.com
Harvard Bioscience (HBIO) director buys 21,000 shares on open market - Stock Titan
Harvard Bioscience CEO Duke buys $25k in shares By Investing.com - Investing.com Australia
Layoff Watch: What are analysts price targets for Harvard Bioscience IncTrade Analysis Report & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Insider Buying: John Duke Acquires 5,000 Shares of Harvard Biosc - gurufocus.com
Harvard Bioscience CEO Duke buys $25k in shares - Investing.com
Harvard Bioscience (HBIO) CEO adds shares and holds major RSU awards - Stock Titan
Harvard Bioscience at KeyBanc Forum: Strategic Growth and Market Focus By Investing.com - Investing.com Canada
Harvard Bioscience 2026 Investor Overview: Translational Science Tools, Growth Strategy, and Financial Outlook - Minichart
Harvard Bioscience (HBIO) Earnings Transcript - AOL.com
Harvard Bioscience Highlights CFO Appointment and Strategic Repositioning - TipRanks
Market Trends: Whats next for Harvard Bioscience Inc stockRisk Management & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Harvard Bioscience provides investor presentation; FY25 results, FY26 guidance and strategic actions - TradingView
Harvard Bioscience (NASDAQ: HBIO) posts FY25 metrics and guides modest 2026 growth - Stock Titan
HBIO: Benchmark Raises Price Target to $6.00, Maintains Speculat - GuruFocus
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split - Investing.com Australia
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split By Investing.com - Investing.com India
Harvard Bioscience Inc (HBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.76%
자본화:
|
볼륨(24시간):